Search results
Results from the WOW.Com Content Network
On Sept. 25, BioAge's stock proceeded with its IPO, which raised gross proceeds of $238.3 million. Before the IPO, it had raised $321 million via several rounds of funding with private investors ...
This year has seen more than its share of successful IPOs – and some giant flops. The extremes should have been expected, in a year with a record number of new public offerings. The second ...
Roivant's technology portfolio also includes Lokavant, which integrates clinical trial data to identify and mitigate risks in pharmaceutical development. [ 7 ] [ 9 ] In 2017, Roivant partnered with the private equity arm of Chinese state-owned CITIC Group to form Sinovant.
IPO 82.4 United States Travis Kalanick, Garett Camp: DiDi: 62 July 2019 [606] June 2021 [607] IPO 73 China Cheng Wei: Facebook 50 January 2011 May 2012 [608] IPO 104 United States Mark Zuckerberg, Eduardo Saverin, Andrew McCollum, Chris Hughes, Dustin Moskovitz: Xiaomi: 45 April 2015 July 2018 [609] IPO 70 China Lei Jun: Alibaba: 42 June 2016 ...
Some 108 companies conducted their IPO in 2023 and raised $19.4 billion, according to Renaissance Capital. Those figures rose markedly from the 2022 doldrums of 71 IPOs and just $7.7 billion raised.
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
Outside of software, the list features six companies driving breakthroughs in biopharmaceuticals and diagnostics. Both energy companies on the Future 50 focus on clean energy, with Adani Green ...
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology.